|
|
Jing Jin Gu, Sander Stegmann, Karen Gathy, Robert Murray, Josee Laliberte, Lanier Ayscue, Beverly S. Mitchell
J Clin Invest. 2000;
106(4):599
doi:10.1172/JCI8669
Abstract |
Full text
| PDF

I
nosine 5′-monophosphate dehydrogenase (IMPDH) is the rate-limiting enzyme in the de novo synthesis of guanine nucleotides, which are also synthesized from guanine by a salvage reaction catalyzed by the X chromosome–linked enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT). Since inhibitors of IMPDH are in clinical use as immunosuppressive agents, we have examined the consequences of knocking out the IMPDH type II enzyme by gene targeting in a mouse model. Loss of both alleles of the gene encoding this enzyme results in very early embryonic lethality despite the presence of IMPDH type I and HPRT activities. Lymphocytes from IMPDH II+/– heterozygous mice are normal with respect to subpopulation distribution and respond normally to a variety of mitogenic stimuli. However, mice with an IMPDH II+/–, HPRT–/o genotype demonstrate significantly decreased lymphocyte responsiveness to stimulation with anti-CD3 and anti-CD28 antibodies and show a 30% mean reduction in GTP levels in lymphocytes activated by these antibodies. Furthermore, the cytolytic activity of their T cells against allogeneic target cells is significantly impaired. These results demonstrate that a moderate decrease in the ability of murine lymphocytes to synthesize guanine nucleotides during stimulation results in significant impairment in T-cell activation and function.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
About CrossRef
| Title and authors |
Publication |
Year |
. |
Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics
T-Y Wu, Y Peng, LL Pelleymounter, I Moon, BW Eckloff, ED Wieben, VC Yee, RM Weinshilboum |
British Journal of Pharmacology |
2010 |
.
|
Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy
Laurent R. Chiarelli, Mariadelfina Molinaro, Carmelo Libetta, Carmine Tinelli, Laura Cosmai, Giovanna Valentini, Antonio Dal Canton, Mario Regazzi |
Br J Clin Pharmacol |
2010 |
.
|
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil
Olivier Gensburger, Ron H.N. Van Schaik, Nicolas Picard, Yannick Le Meur, Annick Rousseau, Jean-Baptiste Woillard, Teun Van Gelder, Pierre Marquet |
Pharmacogenet Genomics |
2010 |
.
|
Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production
Sibylle von Vietinghoff, Hui Ouyang, Klaus Ley |
Kidney Int |
2010 |
.
|
Inosine Monophosphate Dehydrogenase Messenger RNA Expression Is Correlated to Clinical Outcomes in Mycophenolate Mofetil-Treated Kidney Transplant Patients, Whereas Inosine Monophosphate Dehydrogenase Activity Is Not
Ferdi Sombogaard, Annemiek M A Peeters, Carla C Baan, Ron A A Mathot, Monique E Quaedackers, Arnold G Vulto, Willem Weimar, Teun van Gelder |
Ther Drug Monit |
2009 |
.
|
Expression of IMPDH1 and IMPDH2 After Transplantation and Initiation of Immunosuppression
Sara Bremer, Randeep Mandla, Nils T. Vethe, Ingrid Rasmussen, Helge Rootwelt, Pål-D Line, Karsten Midtvedt, Stein Bergan |
Transplantation |
2008 |
.
|
Beyond TPMT: genetic influences on thiopurine drug responses in inflammatory bowel disease
Rebecca L Roberts, Richard B Gearry, Martin A Kennedy, Murray L Barclay |
Future Oncology |
2008 |
.
|
Xenopus cDNA microarray identification of genes with endodermal organ expression
Edmond Changkyun Park, Tadayoshi Hayata, Ken W.Y. Cho, Jin-Kwan Han |
dev dynamics |
2007 |
.
|
Monitoring of Inosine Monophosphate Dehydrogenase Activity as a Biomarker for Mycophenolic Acid Effect: Potential Clinical Implications
Nicole A Weimert, Maurits DeRotte, Rita R Alloway, E Steve Woodle, Alexander A Vinks |
Ther Drug Monit |
2007 |
.
|
Expression of Inosine Monophosphate Dehydrogenase Type I and Type II After Mycophenolate Mofetil Treatment: A 2-year Follow-up in Kidney Transplantation
S Sanquer, P Maison, C Tomkiewicz, I Macquin-Mavier, C Legendre, R Barouki, P Lang |
Clin Pharmacol Ther |
2007 |
.
|
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance
R L Roberts, R B Gearry, M L Barclay, M A Kennedy |
TPJ |
2006 |
.
|
Asymmetric Cell Kinetics Genes: The Key to Expansion of Adult Stem Cells in Culture
James L. Sherley |
Stem Cells |
2002 |
.
|
Mechanism of action of the antitumor agents 6-benzoyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: Potent inhibitors of human type II inosine 5?-monophosphate dehydrogenase
Betsy J. Barnes, Robert A. Izydore, Ann E. Eakin, Iris H. Hall |
Int J Cancer |
2001 |
.
|
Inhibitors of inosine monophosphate dehydrogenase as potential chemotherapeutic agents
Krzysztof W Pankiewicz |
eotp |
2001 |
.
|
|
|
|